Dr. Junck is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1981 - 1983
Stanford Health Care-Sponsored Stanford UniversityResidency, Neurology, 1977 - 1980- Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1976 - 1977
University of Michigan Medical SchoolClass of 1976
Certifications & Licensure
CA State Medical License 1977 - Present
NY State Medical License 1980 - Present
MI State Medical License 1983 - 2026
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- Neurology and climate change.Larry Junck, Ali Saad, Bret Andrews
The Lancet. Neurology. 2024-06-01 - 4 citationsMetabolomic Profiles of Human Glioma Inform Patient Survival.Andrew J Scott, Luis O Correa, Donna M Edwards, Yilun Sun, Visweswaran Ravikumar
Antioxidants & Redox Signaling. 2023-11-01 - 13 citationsCombined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial.Yoshie Umemura, Daniel Orringer, Larry Junck, Maria L Varela, Molly E J West
The Lancet. Oncology. 2023-09-01
Grant Support
- ZD1839 For Recurrent/ Progressive Malig Astrocytoma, Glioblastoma, &MeningiomaNational Center For Research Resources2004
- Phase I/II Trial Of CCI-779 (Nsc# 683864) In Patients W/ Malignant GliomaNational Center For Research Resources2004
- Phase I/II Trial Cpt-11&Temozolomide(Temodar)In Pts.W/Malignant Glioma Umcc 0048National Center For Research Resources2004
- Phase II Study Of Su101 For Patients With Anaplastic ASTNational Center For Research Resources2000–2002
- Su101 Versus Procarbazine For First Relapse Patients W/ GlioblastomaNational Center For Research Resources1999–2002
- Regional Brain Activation In Patients With Brain TumorsNational Center For Research Resources1996–2002
- PET Growth Kinetics And Neuropathology Of Brain TumorsNational Cancer Institute1991–1994
- PETT Studies Of Brain MetabolismNational Institute Of Neurological Disorders And Stroke1988
- PET Studies Of Brain MetabolismNational Institute Of Neurological Disorders And Stroke1985–1987
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
